Targeted cardiometabolic therapeutics
For the millions of patients who struggle
to control diabetes, obesity, hypertension, and
related conditions with current therapies.
Leveraging scientific insights into the intracellular regulation of cortisol, Sparrow is pioneering a novel treatment approach to cardiometabolic disease, starting with type 2 diabetes (T2D).
Our lead candidate, clofutriben, is a HSD-1 inhibitor designed to reduce elevated intracellular cortisol – a key driver of treatment resistance and comorbidities in millions of patients with cardiometabolic disease.
This novel, differentiated, and complimentary mechanism addresses an underlying cause of metabolic morbidity across multiple pathways in varied organ systems and may enable improved glycemic control and metabolic health for patients underserved by existing options.
A new way to treat metabolic morbidity
Nearly half of patients with difficult-to-control diabetes and resistant hypertension have elevated cortisol at levels that increase cardiometabolic risk, yet there are no therapies approved for the vast majority of patients that address this underlying driver of disease.
In patients with diabetes, elevated cortisol acts across multiple organ system pathways to decrease insulin production, increase insulin resistance, and increase gluconeogenesis.
By utilizing a therapy that inhibits HSD-1, we can lower intracellular levels of cortisol in key metabolic tissues to reduce many of the adverse effects of elevated cortisol.
Introducing clofutriben: a highly potent and selective HSD-1 inhibitor
In development for type 2 diabetes:
Millions of patients with type 2 diabetes still struggle to adequately control their blood sugar levels, leaving them exposed to dangerous health risks. New research suggests that elevated cortisol is a highly common driver of treatment resistance and comorbidities.
The targeted agent clofutriben may be perfectly suited to improve glycemic control and metabolic health in this population.
Clofutriben is a once-daily, oral HSD-1 inhibitor designed to reduce intracellular cortisol levels and mitigate the numerous adverse metabolic effects caused or exacerbated by elevated cortisol.
